Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 6Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Prostatic Neoplasms 25Breast Neoplasms 19Multiple Myeloma 17Neoplasm Metastasis 15Lung Neoplasms 15Ovarian Neoplasms 14Lymphoma 14Glioma 14Carcinoma, Renal Cell 14Carcinoma, Non-Small-Cell Lung 12Pancreatic Neoplasms 11Fallopian Tube Neoplasms 11Melanoma 10Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 9Sarcoma 9Medulloblastoma 9Cholangiocarcinoma 9Neuroblastoma 8Glioblastoma 8Colonic Neoplasms 8Triple Negative Breast Neoplasms 7Thyroid Neoplasms 7Oropharyngeal Neoplasms 7Uterine Cervical Neoplasms 6Rhabdoid Tumor 6Rectal Neoplasms 6Neuroendocrine Tumors 6Mouth Neoplasms 6Lymphoma, Non-Hodgkin 6

Interventions

pembrolizumab 3romidepsin 2Specimen Handling 2Melphalan 2Gemcitabine 2Etoposide 2Cyclophosphamide 2Biopsy 210-propargyl-10-deazaaminopterin 2tazemetostat 1talimogene laherparepvec 1prednylidene 1fludarabine 1etoposide phosphate 1durvalumab 1deltacortene 1cc-486 1carmustine, poliferprosan 20 drug combination 1belinostat 1Whole-Body Irradiation 1Triamcinolone 1Tacrolimus 1Prednisone 1Pharmacokinetics 1Pharmacogenomic Variants 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Nivolumab 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, T-Cell × Magnetic Resonance Spectroscopy × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡